Cilostazol Improves Proangiogenesis Functions in Human Early Endothelial Progenitor Cells through the Stromal Cell-Derived Factor System and Hybrid Therapy Provides a Synergistic Effect In Vivo

Figure 6

The role of SDF-1α in the stimulatory effect of cilostazol on proangiogenesis functions in human early EPCs. Anti-SDF-1α neutralizing antibody could significantly suppress the effect of cilostazol on proliferation (a), migration (b), and in vitro vascular tube formation of EPCs (c). , , and , significantly different compared with vehicle-treated cells. , , and versus cilostazol-treated (30 μM) cells. Ab, antibody; BrDU, 5-bromo-2′-deoxyuridine; IgG, immunoglobulin type G; SDF-1α, stromal cell-derived factor-1α.

(a)

(b)

(c)